Progyny, Inc. (NASDAQ:PGNY) Chairman Sells $770,000.00 in Stock

Progyny, Inc. (NASDAQ:PGNYGet Free Report) Chairman David J. Schlanger sold 20,000 shares of Progyny stock in a transaction on Monday, February 5th. The shares were sold at an average price of $38.50, for a total value of $770,000.00. Following the transaction, the chairman now owns 86,312 shares in the company, valued at $3,323,012. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Progyny Trading Down 0.3 %

NASDAQ PGNY opened at $39.79 on Thursday. The stock’s 50 day moving average is $37.31 and its two-hundred day moving average is $35.83. Progyny, Inc. has a 1-year low of $29.44 and a 1-year high of $44.95. The company has a market capitalization of $3.81 billion, a price-to-earnings ratio of 76.52, a PEG ratio of 1.40 and a beta of 1.51.

Progyny (NASDAQ:PGNYGet Free Report) last posted its quarterly earnings data on Tuesday, November 7th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.05. Progyny had a net margin of 5.03% and a return on equity of 11.64%. The firm had revenue of $280.90 million during the quarter, compared to analysts’ expectations of $271.20 million. During the same quarter in the previous year, the company posted $0.13 EPS. Progyny’s revenue was up 36.8% on a year-over-year basis. On average, analysts predict that Progyny, Inc. will post 0.57 earnings per share for the current year.

Institutional Trading of Progyny

Institutional investors and hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. increased its position in shares of Progyny by 10.4% in the 4th quarter. Principal Financial Group Inc. now owns 1,358,399 shares of the company’s stock valued at $50,505,000 after buying an additional 127,830 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Progyny by 14.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 844,679 shares of the company’s stock valued at $31,406,000 after buying an additional 105,544 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Progyny by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,687 shares of the company’s stock valued at $23,969,000 after buying an additional 14,039 shares in the last quarter. FourThought Financial Partners LLC increased its position in shares of Progyny by 1.3% in the 4th quarter. FourThought Financial Partners LLC now owns 32,683 shares of the company’s stock valued at $1,215,000 after buying an additional 423 shares in the last quarter. Finally, Amalgamated Bank increased its position in shares of Progyny by 2.5% in the 4th quarter. Amalgamated Bank now owns 51,558 shares of the company’s stock valued at $1,917,000 after buying an additional 1,236 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

PGNY has been the subject of several research reports. KeyCorp reduced their price objective on Progyny from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 8th. Barclays assumed coverage on Progyny in a research report on Wednesday, January 3rd. They issued an “overweight” rating and a $48.00 target price for the company. Finally, Truist Financial decreased their target price on Progyny from $52.00 to $47.00 and set a “buy” rating for the company in a research report on Wednesday, November 8th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $48.56.

View Our Latest Stock Report on Progyny

About Progyny

(Get Free Report)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.